Inclusion Criteria:  Over 18 years old Diagnosis of migraine before the age of 50, confirmed though screening consultation with the patient Willing and able to provide written informed consent Willing to comply with study assessment schedule and patient diary entry  Diagnosis of migraine, with or without aura based on the following primary headache characteristics (based on the Revised International Headache Society criteria for migraine headache)  At least 5 attacks fulfilling criteria B-D Headache attacks lasting 4-72 hours (untreated or unsuccessfully treated) Headache has at least two of the following characteristics:  i. unilateral location ii. pulsating quality iii. moderate or severe pain intensity iv. aggravation by or causing avoidance of routine physical activity (e.g., walking or climbing stairs) d. During headache at least one of the following: i. nausea and/or vomiting ii. photophobia and phonophobia e. Not attributed to another disorder  Migraine associated with photophobia i.e. either photic hypersensitivity or photic allodynia or inter-ictal photophobia or migraine triggered by light according to patient or a combination of these 4 factors No expected changes of headache preventative medications after enrolment  Exclusion Criteria:  Patients with other light sensitive conditions, such as iritis or retinal disease. Patients who have less than 4 headache days per month Patients who have daily headaches. Pregnant or nursing History of cluster headache or hemiplegic migraine Evidence of seizure or major psychiatric disorder Score of 19 or higher on the BDI Active chronic pain syndrome Cardiac or hepatic disease Have taken any investigational medication within 12 weeks before randomization, or are scheduled to receive an investigational drug Have received Botox injections for any purpose in the head or face region within 3 months of trial onset or scheduled to receive such treatment during the trial Medication overuse as per the revised ICHD-3 IHS criteria Medications that can affect light perception like ethambutol, hydroxychloroquine or amiodarone or any other according to the opinion of the investigator Patients requiring prescription/reading glasses Patients who have not responded to three or more migraine preventive drugs Patients who have a diagnosed neurological disorder that may influence the study according to the investigators